ZIPSYDON
Manufacturer Details
SUN PHARMA
Compositions:
Ziprasidone 20mg/40mg/60mg/80mg tablets,
|
Strength
|
Rate
|
Packing Style
|
|
20mg
|
70.00
|
10s tablets
|
|
40mg
|
128.00
|
10s tablets
|
|
60mg
|
0.00
|
10s tablets
|
|
80mg
|
215.00
|
10s tablets
|
List of Related Indications:
List Of Drugs:
- Ziprasidone - Antipsychotic Agents - Benzisoxazole derivative- (Sep 2004)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
CNS drugs, antihypertensives, Levodopa, antagonists , Carbamazepine, ketoconazole Correct hypokalemia, hypomagnesameia in diuretics
Indication:
Schizophrenia
LIST OF DRUGS DURING 2004
Sr.No- 238
Name of the Drug- Ziprasidone powder for Injection
(after reconstitution 20mg/ml )
Pharmacological Classification- Anti-psychosis
Date of Approval- 03-09-2004
Approved by U.S.FDA on 30-12-2004 (Ref- FDA approved List- 2004)
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Ziprosidone Hcl Schizophrenia 18-03-2002
2.Ziprasidone Powder Anti-Psychotic 03-09-2004
for Injection
(After reconstitution
20mg/ml)
Adverse Reaction:
Somonolence , extrapyrimadal syndrome, Respiratory disorder GI uspset, rash, distonia, Tachycardia, myalgia, postural hypotension, QTc prolongation and risk of sudden death Headache, weight gain, hyperglycemia, Increased risk of death in elderly patients with dementia- related psychosis Prisapism, serotonin syndrome Mania, hypomania, Orofacial edema, urticaria Swollen tongue, facial droop, Enuresis, urinary incontinence Leukopenia, neutropenia Agranulocytosis Discontinue therapy if neutrophil < 1000/mm2
Contra-Indications:
History of QT prolongation Congenital long QT syndrome, recent acute MI uncompensated heart failure, concomittant drugs that cause QT prolongation, including dofetilide , solatol, quinidine, other class Ia and class III antiarrhytmics , mesoridazime. thioridazine, chlorpromazine, pimozide, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic troxide, pobucol, levomethadyl, dolasetron, tracolimus
Special precautions
Hepatic impairment Discontinue if QTc > 500 msec persists Neuroleptic malignant syndrome, or unexplained rash occurs Consider discontinuing if tardive dyskinesia occurs. Conditions that increase risk of torse de pointes ( eg. dizziness, palpitations, syncope )
Cardio- or cerebrovascular disease Risk of hypotension or seizures History of breast cancer Dysphagia, expose to extreme heat, re-evalute periodically Labour and delivery pregnancy and lactation, prescribe lowest possible dose Hyperglycaemia, ketoacidosis, hyperomolar coma or death Diabetic should be monitored regularly for worsening of glucose control Test fasting blood sugar in potentially diabetes with family history Elderly patients with dementia
Dosages/ Overdosage Etc:
Schizophrenia
Dosage-
Administer initial of 20mg twice daily with food In some patients daily dosage subsequently may be adjusted on the basis of individual clinical status up to 80mg twice daily Dosage adjustments should generally occur at intervals of 2 days or more as steady state is acheived within 1 to 3 days
Observe patients for improvement for several weeks before upward adjustments
Pharmacology/ Pharmacokinetics:
GROUP - CENTRAL NERVOUS SYSTEM AGENTS ANTIPSYCHOTIC AGENTS CHEMICAL CLASS - Benzisoxazole Derivatives
Interaction with Food:
To be taken with food
Pregnancy and lactation:
Observe extreme caution if required to be administered during pregnancy and lactation
